Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma

Conditions

• Multiple Myeloma in Relapse

Interventions

• OTHER: The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting.

Sponsor

Odense University Hospital